Abstract:Mechanical stress and pathological signaling trigger the activation of fibroblasts to myofibroblasts, which accelerates extracellular matrix turnover, disrupts normal wound healing and can generate deleterious fibrosis. Myocardial fibrosis independently promotes cardiac arrhythmias, sudden cardiac arrest, and contributes to the severity of heart failure. Fibrosis can also alter cell-to-cell communication and increase myocardial stiffness. Human induced pluripotent stem cell derived cardiac fibroblasts (hiPSC-CFbs) have the potential to enhance clinical relevance in precision disease modeling by facilitating the study of patient-specific phenotypes. However, it is unclear whether hiPSC-CFbs can be activated to become myofibroblasts akin to primary cells, and the key signaling mechanisms in this process remain unidentified. We hypothesize that the passaging of hiPSC-CFbs, similar to primary cardiac fibroblasts, induces specific genes required for myofibroblast activation and increased mitochondrial metabolism. Passaging of hiPSC-CFbs from passage 0 to 3 (P0 to P3) and treatment of P0 with TGFβ1 was associated with a gradual recruitment of genes to initiate the activation of these cells to myofibroblasts, including collagen, periostin, fibronectin, and collagen fiber processing enzymes with concomitant downregulation of cellular proliferation markers. Most importantly, canonical TGFβ1 and Hippo signaling component genes including TAZ were influenced by passaging hiPSC-CFbs. Seahorse assay revealed that passaging and TGFβ1 treatment increased mitochondrial respiration, consistent with fibroblast activation requiring increased energy production, whereas treatment with the glutaminolysis inhibitor BPTES completely attenuated this process. Based on these data, we suggest that hiPSC-CFb passaging enhanced fibroblast activation, influenced fibrotic signaling pathways, and enhanced mitochondrial metabolism approximating what has been reported in primary cardiac fibroblasts. Thus, hiPSC-CFbs may provide an accurate in vitro preclinical model for the cardiac fibrotic condition, which may facilitate the identification of putative anti-fibrotic therapies, including patient-specific approaches.

Automated Prediction of Fibroblast Phenotypes Using Mathematical Descriptors of Cellular Features

Simulation of Atrial Fibrosis Using Coupled Myocyte-Fibroblast Cellular and Human Atrial Models.

Bioengineered in Vitro Tissue Model of Fibroblast Activation for Modeling Pulmonary Fibrosis

Integrated Single Cell Analysis of Human Lung Fibrosis Resolves Cellular Origins of Predictive Protein Signatures in Body Fluids

Ex Vivotissue Perturbations Coupled to Single Cell RNA-seq Reveal Multi-Lineage Cell Circuit Dynamics in Human Lung Fibrogenesis

Deep-Learning-Driven Quantification of Interstitial Fibrosis in Digitized Kidney Biopsies

A strategy to quantify myofibroblast activation on a continuous spectrum

P17 Dissection of the molecular and cellular heterogeneity of dermal fibroblasts in skin fibrosis

Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model

Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model

Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies

Computer-Assisted Algorithm for Quantification of Fibrosis by Native Cardiac CT: A Pilot Study

Imaging of Cardiac Fibrosis: How Far Have We Moved From Extracellular to Cellular?

Real‐Time Measurement of Cell Mechanics as a Clinically Relevant Readout of an In Vitro Lung Fibrosis Model Established on a Bioinspired Basement Membrane

Targeting immune-fibroblast cell communication in heart failure

Fibroblast activation in response to TGFβ1 is modulated by co-culture with endothelial cells in a vascular organ-on-chip platform

Microengineered in Vitro Model of Cardiac Fibrosis Through Modulating Myofibroblast Mechanotransduction.

Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis

Molecular and metabolomic characterization of hiPSC-derived cardiac fibroblasts transitioning to myofibroblasts

A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening

Subtyping based on immune cell fractions reveal heterogeneity of cardiac fibrosis in end-stage heart failure